BioMarin, Catalyst Pharma deal

BioMarin granted Catalyst exclusive, North American rights to Orphan drug Firdapse amifampridine. BioMarin, which is eligible for undisclosed royalties, will invest $5 million

Read the full 236 word article

User Sign In